scispace - formally typeset
C

Chiranjib Pal

Researcher at West Bengal State University

Publications -  49
Citations -  897

Chiranjib Pal is an academic researcher from West Bengal State University. The author has contributed to research in topics: Leishmania donovani & Medicine. The author has an hindex of 14, co-authored 42 publications receiving 747 citations. Previous affiliations of Chiranjib Pal include Indian Institute of Chemical Biology & Brahmananda Keshab Chandra College.

Papers
More filters
Journal ArticleDOI

Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis.

TL;DR: Luteolin has great promise for acting as a lead compound in the chemotherapy of leishmaniasis, a major concern in developing countries, and can be a strong candidate for antileishmanial drug design.
Journal ArticleDOI

Synthesis of a Novel Quinoline Derivative, 2-(2-Methylquinolin-4- ylamino)-N-phenylacetamide—A Potential Antileishmanial Agent

TL;DR: 2-(2-Methylquinolin-4-ylamino)-N-phenylacetamide (2) was found to be significantly more active than the standard antileishmanial drug sodium antimony gluconate (SAG) in reducing the parasite load both in the spleen and liver at a much lower concentration in hamster models.
Journal ArticleDOI

Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis.

TL;DR: Data indicate that DC-based immunotherapy enhances the in vivo antileishmanial potential of antimony or vice versa, andetitive in vitro stimulation of splenocytes from uninfected or L. donovani-infected mice with SLDA-pulsed DCs led to the emergence of CD4+ T cells with characteristics of Th1 cells.
Journal ArticleDOI

Leishmanicidal and Anticandidal Activity of Constituents of Indian Edible Mushroom Astraeus hygrometricus

TL;DR: Two new lanostane‐type triterpenes, 1 and 2, were isolated from Astraeus hygrometricus and exhibited excellent in vitro toxicities against Candida albicans, comparable to standard antifungal antibiotics.